Scopa James Paul's Form 4 filing
DICE Therapeutics, Inc.DICE · filed Mar 21, 2023
- Accession no.
- 0001209191-23-020299
- Filed
- Mar 21, 2023
- Trade date
- Oct 24, 2022-Mar 17, 2023
- Filing delay
- 148 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $290.5K. It was filed 148 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scopa James PaulCIK 0001356950 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 24, 2022 | Common Stock | GGiftDisposed | −30,719 | $0.00 | $0 | 22,122 | Direct | |
| Oct 24, 2022 | Common Stock | GGiftAcquired | +30,719 | $0.00 | $0 | 33,719 | Indirect | |
| Mar 17, 2023 | Common Stock | SSaleDisposed | −10,000 | $29.05 | −$290,500 | 23,719 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.